Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis

NCT04339127 | Unknown

• 1 other identifier: NMDARE-HSE
• Study Type: observational
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

Herpes Simplex Virus encephalitis is the most common infectious encephalitis, with an estimated annual incidence of 1 / 250,000 to 1 / 500,000 in industrialized countries. Despite a widely used antiviral treatment, the prognosis remains poor with a mortality of 5 to 20% and a considerable morbidity rate. One of the contributing factors of bad prognosis is the development of encephalitis mediated by autoantibodies, most often directed against NMDA receptors, in the weeks following viral encephalitis. The description of this pathology is recent, the pathophysiology of this process remains poorly understood, and the management of these patients is not yet codified.

Conditions

Autoimmune Encephalitis; Anti NMDA Receptor Encephalitis; Herpetic Encephalitis

Outcome Measures

Primary Outcomes (1)

• Details of clinical, biological, imaging, therapeutic characteristics and patient's evolution.

  Retrospective collection of clinical, diagnostic and therapeutic data, evolution at 6 and 12 months.

  at 6 and 12 months

Study Arms (1)

Cohort NMDARE-HSE

Patients developing clinical autoimmune encephalitis with anti-NMDA antibodies after a herpetic encephalitis, managed by the National Reference Center for Paraneoplastic Syndromes and Autoimmune Encephalitis at the Neurological Hospital of Bron.

Other: Description and analysis

Interventions

Description and analysis OTHER

Retrospective, non-interventional study, using clinical, biological, radiological and therapeutic data collected during the initial diagnosis and follow-up.

Cohort NMDARE-HSE

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

12 patients diagnosed between January 2014 and January 2020

You may qualify if:

• Clinical autoimmune encephalitis with anti-NMDA antibodies and documented by CBA in the CSF
• After a herpetic encephalitis documented by a positive viral PCR for HSV in the CSF
• Without age limit

Sponsors & Collaborators

• Hospices Civils de Lyon: lead

Study Sites (1)

Hospice Civils de Lyon

Bron, 69500,, France

RECRUITING

MeSH Terms

Conditions

Autoimmune Diseases of the Nervous System; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Encephalitis, Herpes Simplex

Condition Hierarchy (Ancestors)

Nervous System Diseases; Autoimmune Diseases; Immune System Diseases; Paraneoplastic Syndromes, Nervous System; Nervous System Neoplasms; Neoplasms by Site; Neoplasms; Paraneoplastic Syndromes; Encephalitis; Brain Diseases; Central Nervous System Diseases; Neurodegenerative Diseases; Neuroinflammatory Diseases; Encephalitis, Viral; Central Nervous System Viral Diseases; Central Nervous System Infections; Infections; Infectious Encephalitis; Virus Diseases; Herpesviridae Infections; DNA Virus Infections

Study Officials

• Jérôme Honnorat

  National Reference Center of autoimmune encephalitis

  STUDY DIRECTOR

Central Study Contacts

Jérôme Honnorat, PhD

CONTACT

04 72 35 78 06; jerome.honnorat@chu-lyon.fr

Géraldine PICARD

CONTACT

0472355842; geraldine.picard@chu-lyon.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 6, 2020
• First Posted: April 9, 2020
• Study Start: April 1, 2020
• Primary Completion: June 1, 2020
• Study Completion: October 1, 2020
• Last Updated: April 9, 2020

Record last verified: 2020-04

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)